Schizophrenia

While psychedelics may have therapeutic potential, their use carries significant risk, particularly for those most vulnerable to psychosis.

Affecting up to 1 percent of the global population, schizophrenia is a rare but debilitating condition that makes it difficult for one to know what’s real.

Bethany Yeiser is now free of severe schizophrenia symptoms after starting clozapine in 2008, allowing her to graduate college and start the CURESZ Foundation.

A new study published in the Science Advances journal offers hope for schizophrenia patients.

While psychedelics may have therapeutic potential, their use carries significant risk, particularly for those most vulnerable to psychosis.

Affecting up to 1 percent of the global population, schizophrenia is a rare but debilitating condition that makes it difficult for one to know what’s real.

Bethany Yeiser is now free of severe schizophrenia symptoms after starting clozapine in 2008, allowing her to graduate college and start the CURESZ Foundation.

A new study published in the Science Advances journal offers hope for schizophrenia patients.